Executive Summary
Our FDA: Drug & Device Team analyzes the Food and Drug Administration’s new guidance on Bayesian approaches to innovative drug trials, providing greater clarity on how companies may design and conduct studies.
- The Bayesian method is a continuous learning process that’s more efficient than current trial standards
- The guidance explains how Bayesian analytics may be used for interim adaptations and dose selection
- Alignment with the European Medicines Agency’s workplan may allow sponsors to design a single study for multiple regulatory jurisdictions
On January 9, 2026, the FDA published a draft guidance on its website clarifying how Bayesian approaches can be used in clinical trials to support regulatory decision-making. This guidance reflects the FDA’s ongoing commitment to innovative trial designs that can accelerate approvals, especially for treatments addressing unmet medical needs.
The FDA’s current gold standard for drug approval is the randomized controlled trial, which usually takes four to five years to complete. These trials use frequentist statistics, a method that answers the question, “If the drug doesn’t work, how likely is it that we would see results this strong just by chance?” Frequentist analysis starts with the assumption that the drug has no effect (the null hypothesis) and calculates the probability of getting results as extreme as those observed. If that probability is very low, the null hypothesis is rejected, and the drug is considered effective.
The Bayesian approach works differently. Instead of relying on a single hypothesis test at the end of a trial, Bayesian methods combine prior knowledge with new data as it becomes available. This continuous learning process estimates the probability that a treatment works and allows trial designs to adapt as evidence grows. The result is greater efficiency and less exposure of patients to treatments that may not be effective. Historically, however, Bayesian methods have been used mainly in early-phase or exploratory studies, and their use in large Phase III trials has been rare.
Bayesian principles are not new to global regulatory frameworks. International Council for Harmonisation (ICH) ICH E9 (Statistical Principles for Clinical Trials), effective since 1998, permits Bayesian methods when the rationale and robustness are clear. ICH E11A (Pediatric Extrapolation), finalized in 2024, supports pediatric drug development using Bayesian extrapolation. Most recently, the ICH E20 (Adaptive Designs for Clinical Trials) draft guideline highlights the benefits of Bayesian approaches in adaptive confirmatory trials.
The FDA’s new draft guidance provides clarity for sponsors interested in using Bayesian methods in clinical trial development. It specifically addresses Bayesian methods for primary inference in Phase III settings and lays out how Bayesian analytics may guide interim adaptations and dose selection, in addition to end-of-trial conclusions. Importantly, it applies broadly to investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), and supplements to these applications—indicating the FDA’s intent to support Bayesian approaches at all stages of drug development.
This guidance also aligns with the European Medicines Agency’s (EMA) 2025–2026 workplan to accelerate clinical trials. The EMA oversees medicines for all European Union Member States and countries in the European Economic Area. Its broad jurisdiction means that harmonization between the FDA and EMA should help reduce uncertainty, streamline trial planning, and enable sponsors to design a single study that supports regulatory submissions in multiple regulatory jurisdictions.
In recent years, the FDA has been actively promoting innovation in trial design. Since 2024, its Center for Clinical Trial Innovation (C3TI) has partnered with sponsors to explore Bayesian approaches. Through the C3TI Demonstration Program, sponsors can submit proposals for non-adaptive Bayesian trials; through the Complex Innovative Trial Design Meeting Program, sponsors can submit proposals for complex adaptive designs. These initiatives underscore the FDA’s commitment to modernizing clinical research. The new draft guidance reflects the FDA’s growing experience and confidence in applying Bayesian methods to support innovative clinical trial designs.
This draft guidance is especially relevant for sponsors in oncology and rare disease development, where patient recruitment is difficult, data sources are diverse, and trial designs must adapt dynamically. Use of Bayesian methods in these trials will enable sponsors to be more nimble and react to observed signals in a way that is potentially more beneficial to these patient cohorts.
Companies may want to begin assessing whether their development program could benefit from Bayesian approaches. It would also be advantageous to evaluate internal capabilities and consider engaging in early conversations with the FDA to stay ahead of evolving expectations.
While guidance documents are nonbinding, they often shape review practice. Interested parties can submit comments on the draft guidance to Docket No. FDA-2025-D-3217. Alston & Bird is following this issue closely, and we look forward to assisting clients as they consider engaging in this new approach with the FDA.
[View source.]
